Proteins

Product Data Sheet



Narsoplimab

Cat. No.: HY-P99376 CAS No.: 2108782-45-0 Target: SARS-CoV Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 ^[1] .	
In Vitro	Narsoplimab (100 nM; 3 h; Vero E6 cells and Vero E6 cells with SARS-CoV-2) inhibits the N protein potentiated MASP-2 deposition ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Narsoplimab (10 mg/kg; i.v.; WT and Masp2 ^{-/-} (KO) mice) decreases percentage of lymphocytes (Lym%) and increases percentage of neutrophils (Neu%) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	WT and Masp2 ^{-/-} (KO) mice (C57BL/6N, female, 12-15 weeks old) ^[1]
	Dosage:	10 mg/kg
	Administration:	Intravenous injection
	Result:	Decreased percentage of lymphocytes (Lym%) and an increased percentage of neutrophils (Neu%).

REFERENCES

[1]. Gao T, et, al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduct Target Ther. 2022 Sep 14;7(1):318.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1